However, unlike at first progression following monotherapy (16), genomic MSI, measured by the tumor MMRDness scores (Methods; ref. 30) failed to significantly stratify post-salvage survival once patients had progressed after anti–PD-1 monotherapy (Fig. 2C). Here, PDCD1 is linked to neoplasm.